Intratumoral N17350 in Advanced Solid Tumors
A phase 1/2 trial of N17350 in melanoma, head and neck squamous cell carcinoma and non-small-cell lung cancer, run by Onchilles Pharma Inc, now recruiting.
Overview
Intratumoral N17350 in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07339176 by Onchilles Pharma Inc, with 275 participants planned, started 2026-05-25 and due to reach its primary completion in 2028-07. Interventions recorded: N17350.
Similar pages
not linked directly; found by shared links- TrialA Study of DM005 in Patients With Advanced Solid Tumors
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
- TrialStudy of GV20-0251 in Participants With Solid Tumor Malignancies
Shares Head and neck squamous cell carcinoma, Melanoma, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Shares Head and neck squamous cell carcinoma, Melanoma, Non-small-cell lung cancer and the tag pipeline.
- TrialPhase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
- TrialMIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialFID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma
Shares Head and neck squamous cell carcinoma and the tag pipeline.